drugset / Trial / NCT06773663
Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism
NaSingle-groupOpen-labelDiagnostic
Summary
This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-Pentixafor PET imaging in patients with primary aldosteronism. And evaluates the potential of Al18F-NOTA-Pentixafor PET imaging in surgical strategy guidance.
Timeline
- Start
- 2023-12-30
- Primary completion
- 2026-05-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Al18F-NOTA-Pentixafor | Diagnostic / imaging agent | 4.81 mbq/kg | Intravenous |